Price movement over the last 24 hours
ADMA Biologics Inc vs Corning Incorporated — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Corning Incorporated trades at $184.5 (market cap $159.55B). The key difference: Corning Incorporated is far larger — about 74.9× ADMA Biologics Inc's market cap, and Corning Incorporated pays a 0.6% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GLW | |
|---|---|---|
Market Cap | $2.13B | $159.55B |
Sector | Health | Technology |
52-Week High | $20.38 | $255.79 |
52-Week Low | $7.60 | $51.60 |
Enterprise Value | $2.20B | $167.71B |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Corning Inc. (GLW) trades at $185.38, down 5.75% amid recent AI-related stock volatility, yet maintains strong fundamentals with Q1 2026 EPS beating estimates at $0.70. Revenue grew to $15.63B in 2025, with net income margin improving to 10.21%. Technical indicators show a bullish overall signal despite near-term bearish moving averages, with key support at $185. Recent news highlights AI-driven fiber demand as a growth catalyst, though competition and China exposure pose risks.
The outlook remains positive with a consensus price target of $206.60, implying 11.4% upside, supported by 54% analyst buy ratings. Risks include high valuation multiples (P/E 93.65) and dependency on AI infrastructure spending cycles. Institutional sentiment is bullish, but investors should monitor earnings consistency and macroeconomic pressures on tech stocks.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →